NASDAQ : CTMX
CytomX Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.34 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 509.88M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 509.88M |
| Enterprise Value | 185.31M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 217.90M |
| Shares Outstanding | 217.90M |
| Shares Change (YoY) | +88.30% |
| Shares Change (QoQ) | +23.50% |
| Owned by Insiders (%) | 0.57% |
| Owned by Institutions (%) | 87.39% |
| Float | 179.66M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 27.86 |
| Forward PS | 19.28 |
| PB Ratio | 1.69 |
| P/TBV Ratio | 1.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 10.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.36 |
| Quick Ratio | 9.26 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -37.75% |
| Return on Assets (ROA) | -19.58% |
| Return on Invested Capital (ROIC) | -25.07% |
| Return on Capital Employed (ROCE) | -25.53% |
| Weighted Average Cost of Capital (WACC) | 16.19% |
| Revenue Per Employee | $265,261 |
| Profits Per Employee | -$1.20M |
| Employee Count | 69 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 231,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.20 |
| 52-Week Price Change | -28.22% |
| 50-Day Moving Average | 2.83 |
| 200-Day Moving Average | 3.87 |
| Relative Strength Index (RSI) | 42.65 |
| Average Volume (20 Days) | 3,551,916 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 42.79M |
| Short Previous Month | 40.81M |
| Short % of Shares Out | 19.64% |
| Short % of Float | 23.82% |
| Short Ratio (days to cover) | 10.43 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 18.30M |
| Gross Profit | 18.30M |
| Operating Income | -87.15M |
| Pretax Income | -79.42M |
| Net Income | -82.66M |
| EBITDA | -86.21M |
| EBIT | -87.15M |
| Loss Per Share | -$0.45 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 330.28M |
| Total Debt | 5.70M |
| Net Cash | 324.58M |
| Net Cash Per Share | $1.49 |
| Equity (Book Value) | 302.07M |
| Book Value Per Share | 1.39 |
| Working Capital | 333.29M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -82.41M |
| Capital Expenditures | -74,000 |
| Depreciation & Amortization | 942,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -82.48M |
| FCF Per Share | -$0.38 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -476.17% |
| Pretax Margin | -433.93% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -88.30% |
| Shareholder Yield | -88.30% |
| Earnings Yield | -19.44% |
| FCF Yield | -16.18% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $12.25 |
| Price Target Difference | 423.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | -27.86% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.72 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |